Navigating the Evolving Treatment Landscape of Renal Cell Carcinoma to Ensure Equitable Access to Quality Care
June 30, 2023
June 30, 2024
This activity is jointly provided by Talem Health and RME Collaborative.
This online program is recorded content from the live session at Oncology Congress and is co-supported by independent medical education grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Eisai, Inc.; GlaxoSmithKline; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; and Seagen. This activity is supported by independent medical education grants from Eisai, Inc.; and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hour (0.75 contact hour of pharmacotherapy credit)
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Therapeutic options for metastatic renal cell carcinoma (RCC) have expanded over the last decade and now include targeted therapies as well as immunotherapies. However, workforce shortages, low rates of recruitment into clinical trials, racial and socioeconomic inequities, and transportation issues have all limited access to these advancements in rural and underserved communities. Oncology teams in these settings are also challenged to stay up to date on rapidly evolving clinical evidence and guidance, further contributing to disparities in cancer care. In this activity, expert faculty will review available therapies for metastatic RCC as well as current guideline recommendations and clinical evidence for individualizing treatment in the first- and subsequent-line settings. Evidence-based strategies to identify and overcome barriers to RCC management in rural and underserved areas will also be discussed.
This enduring activity is a recorded session from Oncology Congress that took place on April 1, 2023.
Upon completion of this activity, participants should be better able to:
- Evaluate available therapies for metastatic RCC based on their efficacy and safety profiles
- Apply the latest guidelines and clinical evidence into the development of treatment plans for patients with metastatic RCC in the first- and subsequent-line settings
- Implement evidence-based strategies for reducing disparities in RCC care in rural and underserved communities
Martin H. Voss, MD
Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Chris Prakash, MD
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris
Joint Accreditation Statement
In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.75 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
All relevant financial relationships have been mitigated.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:
Martin H. Voss, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Affimed, AVEO Oncology, Eisai, Inc., Exelixis, Inc., Genentech, Inc., Merck & Co., Inc., MicuRx Pharmaceuticals, Inc., and Oncorena; grant/research support from AstraZeneca Pharmaceuticals, Bristol Myers Squibb, Merck & Co., Inc., Pfizer, Inc., and Roche/Genentech, Inc.
Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.
Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.
Instructions for Participation and Credit
This activity is offered at no cost to participants. To receive CME credit, participants must:
- Read the CME/CE information, including learning objectives and disclosure statements.
- Complete the pre-test.
- View the online activity.
- Complete the post-test and evaluation form.
A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.
There is no fee for this educational activity.
For general information or questions about this activity, please contact RME Collaborative ( a division of Talem Health ) at 800-913-9370 firstname.lastname@example.org.